Fixed combination brimonidine-timolol versus brimonidine for treatment of intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy. 2012

Veysi Öner, and Mehmet Fuat Alakuş, and Mehmet Taş, and Kemal Türkyılmaz, and Yalçın Işcan
Department of Ophthalmology, Recep Tayyip Erdoğan University Medical School, Rize, Turkey. veysioner@gmail.com

OBJECTIVE To evaluate the efficacy of fixed combination brimonidine-timolol (FCBT) in comparison with brimonidine tartrate 0.2% and control for the treatment of intraocular pressure (IOP) spikes after neodymium:YAG (Nd:YAG) laser posterior capsulotomy. METHODS One hundred five eyes of 105 patients were enrolled in the study. Patients were randomized to 3 groups (each group, including 35 patients): the FCBT group that received 1 drop of FCBT, the brimonidine group that received 1 drop of brimonidine tartrate 0.2%, and the control group that received 1 drop of artificial tear, 1 h before the laser procedure. Postoperative IOP measurements were performed at 1st, 2nd, 3rd, 24th hours, and seventh day. RESULTS The mean IOP changes from baseline were statistically different between the study groups at first, second, and third hours (all P<0.001). Pairwise comparisons showed that although the mean IOP changes of the treatment groups were similar at 1st and 24th hours and seventh day (all P>0.05), the IOP levels of the brimonidine group were less reduced from baseline than the FCBT group at second and third hours (P=0.01 and P=0.03, respectively). The differences among the study groups concerning the incidence of IOP elevations of ≥5 or ≥10 mmHg were statistically significant (P=0.007, P=0.04, respectively). However, the differences between the treatment groups were not statistically significant (both P>0.05). CONCLUSIONS This study has shown that preoperative instillation of 1-drop FCBT was safe and effective for preventing IOP spikes after Nd:YAG laser posterior capsulotomy. FCBT may be a better option than brimonidine tartrate 0.2%, which is one of the current standard prophylaxes for these spikes.

UI MeSH Term Description Entries
D007429 Intraocular Pressure The pressure of the fluids in the eye. Ocular Tension,Intraocular Pressures,Ocular Tensions,Pressure, Intraocular,Pressures, Intraocular,Tension, Ocular,Tensions, Ocular
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011300 Preoperative Care Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed) Care, Preoperative,Preoperative Procedure,Preoperative Procedures,Procedure, Preoperative,Procedures, Preoperative
D011810 Quinoxalines Quinoxaline
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068438 Brimonidine Tartrate A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate,5-bromo-6-(imidazolidinylideneamino)quinoxaline,5-bromo-6-(imidazolin-2-ylamino)quinoxaline,AGN 190342,AGN-190342,Alphagan,Alphagan P,Brimonidine,Brimonidine Purite,Brimonidine Tartrate (1:1),Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer,Brimonidine Tartrate, (R-(R*,R*))-Isomer,Bromoxidine,Mirvaso,Ratio-Brimonidine,Sanrosa,UK 14,304,UK 14,304-18,UK 14304,UK 14308,UK-14,304-18,UK-14,308,UK-14304,AGN190342,Ratio Brimonidine,UK 14,304 18,UK 14,30418,UK 14,308,UK14,30418,UK14,308,UK14304

Related Publications

Veysi Öner, and Mehmet Fuat Alakuş, and Mehmet Taş, and Kemal Türkyılmaz, and Yalçın Işcan
April 2018, Journal of cataract and refractive surgery,
Veysi Öner, and Mehmet Fuat Alakuş, and Mehmet Taş, and Kemal Türkyılmaz, and Yalçın Işcan
September 1997, Journal of cataract and refractive surgery,
Veysi Öner, and Mehmet Fuat Alakuş, and Mehmet Taş, and Kemal Türkyılmaz, and Yalçın Işcan
September 2006, Journal of cataract and refractive surgery,
Veysi Öner, and Mehmet Fuat Alakuş, and Mehmet Taş, and Kemal Türkyılmaz, and Yalçın Işcan
January 2000, Ophthalmic surgery and lasers,
Veysi Öner, and Mehmet Fuat Alakuş, and Mehmet Taş, and Kemal Türkyılmaz, and Yalçın Işcan
January 2011, American journal of ophthalmology,
Veysi Öner, and Mehmet Fuat Alakuş, and Mehmet Taş, and Kemal Türkyılmaz, and Yalçın Işcan
January 2017, Journal of ophthalmology,
Veysi Öner, and Mehmet Fuat Alakuş, and Mehmet Taş, and Kemal Türkyılmaz, and Yalçın Işcan
April 2007, Current medical research and opinion,
Veysi Öner, and Mehmet Fuat Alakuş, and Mehmet Taş, and Kemal Türkyılmaz, and Yalçın Işcan
February 2011, Journal of cataract and refractive surgery,
Veysi Öner, and Mehmet Fuat Alakuş, and Mehmet Taş, and Kemal Türkyılmaz, and Yalçın Işcan
February 2008, International ophthalmology,
Veysi Öner, and Mehmet Fuat Alakuş, and Mehmet Taş, and Kemal Türkyılmaz, and Yalçın Işcan
July 2004, Journal of cataract and refractive surgery,
Copied contents to your clipboard!